{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.262"}]}],"title":"Heart SUVRmean change (%) - dFLC change"},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.619"}]}],"title":"Heart SUVRmean change (%) - κ/λ ratio change"},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.252"}]}],"title":"Change in SUVRmean absolute - dFLC change"},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.515"}]}],"title":"Change in SUVRmean absolute - κ/λ ratio change"},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.405"}]}],"title":"Heart SUVRmean change (%) - Baseline dFLC"},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.929"}]}],"title":"Heart SUVRmean change (%) - Repeat dFLC"},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.491"}]}],"title":"Change in SUVRmean absolute - Baseline dFLC"},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.970"}]}],"title":"Change in SUVRmean absolute - Repeat dFLC"}],"denoms":[{"counts":[{"groupId":"OG000","value":"9"}],"units":"Participants"}],"description":"For AL patients, correlate visual and quantitative changes in organ-specific 124I-AT-01 uptake (percent change in radiotracer uptake from baseline) with change in serum free light chains over the period between imaging studies, when available in the medical record.\n\nBaseline assessments reflect the values assessed during the previous study (NCT03678259). Repeat assessments reflect the values assessed during this current study. The 'change in' values are calculated as the repeat value from this current study minus the baseline value from the previous study (NCT03678259).","groups":[{"description":"Experimental: Patients will receive a single IV injection of 124I-AT-01 radiotracer and PET/CT imaging\n\nIn this repeat imaging study, patients previously enrolled in the AMY1001 study, in whom positive PET/CT imaging findings were observed will undergo repeat imaging to assess changes in radiotracer uptake in the liver, spleen, heart and kidneys.","id":"OG000","title":"All Participants"}],"paramType":"NUMBER","populationDescription":"Of the 19 total enrolled participants, this analysis is limited to the 9 patients with AL amyloidosis because evaluating the difference between involved and uninvolved serum free light chains (dFLC) is clinically relevant only to that cohort. Correlation (Spearman) analyses were performed to assess the relationship between the change in radiotracer uptake (SUVR) and changes in dFLC and the free κ/λ ratio.","reportingStatus":"POSTED","timeFrame":"Baseline (assessed during previous study NCT03678259) and Repeat Assessment (Day 1 to Day 2 of current study)","title":"Measure of Interest","type":"OTHER_PRE_SPECIFIED","unitOfMeasure":"spearman correlation coefficient"}